Eli Lilly and Company $LLY Holdings Decreased by Tompkins Financial Corp

Tompkins Financial Corp reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 2.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,289 shares of the company’s stock after selling 638 shares during the period. Eli Lilly and Company comprises about 1.9% of Tompkins Financial Corp’s holdings, making the stock its 11th largest holding. Tompkins Financial Corp’s holdings in Eli Lilly and Company were worth $23,111,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of LLY. Brighton Jones LLC grew its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares during the period. Kaufman Rossin Wealth LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at $242,000. EntryPoint Capital LLC acquired a new stake in Eli Lilly and Company during the first quarter valued at $330,000. Finally, GDS Wealth Management acquired a new position in Eli Lilly and Company in the 1st quarter worth about $283,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have commented on LLY shares. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Berenberg Bank raised their target price on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday, December 2nd. UBS Group reissued a “neutral” rating on shares of Eli Lilly and Company in a research report on Thursday. Finally, Sanford C. Bernstein boosted their price objective on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the stock an “outperform” rating in a research report on Monday, November 24th. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,141.73.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,056.57 on Friday. The firm has a market capitalization of $998.86 billion, a PE ratio of 51.69, a price-to-earnings-growth ratio of 1.31 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99. The firm has a 50-day moving average price of $956.00 and a 200 day moving average price of $828.10.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the company posted $1.18 EPS. The company’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.